Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Current Assets (2018 - 2025)

10x Genomics' Current Assets history spans 8 years, with the latest figure at $684.5 million for Q4 2025.

  • For Q4 2025, Current Assets rose 17.12% year-over-year to $684.5 million; the TTM value through Dec 2025 reached $684.5 million, up 17.12%, while the annual FY2025 figure was $684.5 million, 17.12% up from the prior year.
  • Current Assets for Q4 2025 was $684.5 million at 10x Genomics, up from $659.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $757.2 million in Q2 2021 and bottomed at $562.3 million in Q3 2023.
  • The 5-year median for Current Assets is $632.2 million (2022), against an average of $643.5 million.
  • The largest annual shift saw Current Assets surged 73.53% in 2021 before it dropped 15.41% in 2022.
  • A 5-year view of Current Assets shows it stood at $747.6 million in 2021, then dropped by 15.06% to $635.0 million in 2022, then fell by 6.14% to $596.0 million in 2023, then dropped by 1.95% to $584.4 million in 2024, then increased by 17.12% to $684.5 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Current Assets are $684.5 million (Q4 2025), $659.8 million (Q3 2025), and $655.7 million (Q2 2025).